Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA Lung-202: Pumitamig vs Pembrolizumab in Advanced NSCLC
NCT07361510Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Primary completion
- Oct 2031
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial of pumitamig in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-free Survival by Blinded Independent Central Review at 3 years and Overall survival at 5 years. Started Mar 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07361510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361510.